Kornimate/medical-research-clean huggingface dataset:
favipiravir plus hydroxychloroquine and lopinavir/ritonavir plus hydroxychloroquine in covid-19

Conditions: COVID-19; Favipiravir; Kaletra; Hydroxychloroquine; Lopinavir/Ritonavir

Summary: this is an open-label, non-randomized clinical trial study. the number of 40 covid-19 patients with moderate severity will be admitted in progressive care units (pcus) and intensive care units (icus) enrolled in the study. the sampling will be purposive and based on the same independent variables, including age, gender, past medical histories, and the situation of the patient at the admission day, and ventilator support. the patients will be allocated into two groups with different regimens. group "a" (regimen a)will be defined as favipiravir 1600 mg a first dose and 600 mg in 3 divided doses daily plus 400 mg in 2 divided doses of hydroxychloroquine every day. the group "b" (regimen b) will be contained 400 mg of lopinavir/ritonavirin 2 divided doses plus the first dose (400 mg) of hydroxychloroquine. hydroxychloroquine will not be used for adverse drug reactions. the regimen remained at least 7 up to 10 days. data will be analyzed using statistical package for social sciences (spss) version 18 (spss inc. chicago, il, usa) for windows. the variables will be compared using independent and paired t-test for normally distributed variables and wilcoxon, chi-square for non-normal distributed variables. the kaplan meier test will be used for survival analysis and the one-sample kolmogorov-smirnov test for the evaluation of distributions.


Eligibility criteria:
inclusion criteria: * diagnosis of covid-19 based on either ground glass appearance in chest ct scan or positive rt-pcr test for covid-19 * requiring hospitalization * patient's age between 16 and 100 years * signed informed consent form exclusion criteria: * receiving other antiviral medications such as (kaletra, ribavirin, oseltamivir) * chronic liver or renal failure * hiv; gi bleeding * pregnancy * lactation * qt interval \> 500 ms.
a coaching intervention to young adults with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the treatment burden for patients with cystic fibrosis (cf) is significant and poor adherence has been well-documented. the investigators hypothesize that a coaching intervention will empower young adults with cf to manage their lives with cf and improve health-related quality of life (hrqol). the main aim of the study is to establish the feasibility and acceptability of a life-coaching intervention.


Eligibility criteria:
inclusion criteria: * diagnosed with cystic fibrosis (cf), confirmed by clinical findings, identification of two disease-causing cf- mutations, and a positive sweat test * patient at the copenhagen cf centre exclusion criteria: * severe intellectual impairment or insufficient mastery of the danish language, determined by incapacity to independently complete the questionnaires

Keywords: feasibility study coaching health related quality of life adherence
attention-deficit/hyperactivity disorder translational center for identifying biomarkers

Conditions: Attention-deficit/Hyperactivity Disorder

Summary: the purpose of this study was to identify genetic, brain morphologic, and environmental biomarkers that contribute to the pathophysiology of attention-deficit/hyperactivity disorder (adhd).

the investigators planned to recruit adhd and healthy controls from the age of 6 to 17. genetic data including dopamine, norepinephrine, serotonin, neurotropic factors, glutamate-related genes will be genotyped. environmental disruptors including phthalate and cotinine will be analyzed. brain mri data including t1, diffusion tensor imaging (dti), resting state functional mri (rsfmri) will be obtained. neuropsychological tests including continuous performance test, stroop test, children's color trail test, wisconsin card sorting test will be conducted. the investigators plan to identify biomarkers of adhd using an integrative approach of genetic, environmental, neuroimaging and clinical data.

Eligibility criteria:
inclusion criteria: * a diagnosis of attention-deficit/hyperactivity disorder confirmed using the kiddie-schedule for affective disorders and schizophrenia - present and lifetime version- korean version (k-sads-pl-k). * iq over 70 exclusion criteria: * intelligence quotient (iq) \< 70 * a hereditary genetic disorder * a current/past history of brain trauma, organic brain disorder, seizure, or any neurological disorder * autism spectrum disorder, communication disorder, or learning disorder * schizophrenia or any other childhood-onset psychotic disorder * major depressive disorder or bipolar disorder * tourette's syndrome or chronic motor/vocal tic disorder * obsessive-compulsive disorder * a history of methylphenidate treatment lasting more than 1 year or received within the previous 4 weeks
collection of fujifilm's 3dimensional mammograms

Conditions: Breast Cancer

Summary: this image-acquisition study is designed to acquire the study image data and establish and document the clinical findings for each subject. the acquired data will be used to support fujifilm protocol fmsu2011-003b (clinical evaluation of fujifilm 3dimensional digital mammography) and future regulatory submissions.

this is an image acquisition reader study to observe differences between 3d fujifilm mammography and 2d approved mammography

Eligibility criteria:
inclusion criteria: * female. * any ethnic or racial origin. * must come through the study via the screening or diagnostic pathway described above. * have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. * meet none of the exclusion criteria. exclusion criteria: * • presence of a breast implant. * women with only a single breast; for example, post mastectomy patients. * is pregnant or believes she may be pregnant. * a woman who has delivered and who has expressed the intention to breast-feed or is currently breast-feeding. * a woman who has significant existing breast trauma. * have self-reported severe non-focal or bilateral breast pain affecting subject's ability to tolerate mammography examinations. * a woman who has had a mammogram performed for the purpose of therapy portal planning. * inadequate technical quality mammography images, such as insufficient anatomical coverage or significant motion artifacts. * cannot, for any known reason, undergo follow-up mammography examinations (where clinically indicated) at the participating institution. * is an inmate (see us code of federal regulations 45cfr46.306).

Keywords: screening mammogram diagnostic mammogram benign malignant bi-rads categories
improving patient motivation and participation in rehabilitation program through social games

Conditions: Stroke

Summary: this 12-week randomized controlled trial involves two intervention groups (i.e., single-player game group, competition game group) and one control group (i.e., conventional checkerboard group). the main objective of this study is to examine the effects of game-based training on patient motivation, exercise duration, and functional outcomes in comparison with the control group.

a 12-week three-arm randomized controlled trial was conducted to compare the effects between the single-player game, competitive game and a control group (i.e. conventional training) on the motivation, exercise duration and functional improvement in a rehabilitation program. a mix of quantitative method (i.e., questionnaire) and qualitative methods (i.e., interview and observation) were used. the outcome measurements were: (1) motivation: intrinsic motivation inventory (imi), (2) participation: exercise duration, (3) functional improvement: nine-hole peg test (nhpt) and box and block test (bbt), and (4) user feedback.

Eligibility criteria:
inclusion criteria: 1. age≥65 years 2. has neurological disorders (e.g. cerebrovascular accident) with the need of upper limb rehabilitation; 3. able to stand or sit unsupported for 10 minutes; 4. discharged from hospital and living in community; 5. able to communicate either in english or mandarin; and 6. able to provide informed written consent. exclusion criteria: 1. has severe cognitive impairments (mini-mental state examination (mmse) score \<10), 2. with serious cardiorespiratory conditions, 3. with capacity but do not wish to sign the consent form.

Keywords: stroke upper limb rehabilitation neuro-rehabilitation
safety and efficacy study of grt6005 in patients with osteoarthritis (oa) knee pain

Conditions: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Summary: the purpose of this study is to evaluate the safety and efficacy of grt6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (oa) of the knee. this study includes a maximum 21 day screening period followed by a 15-week double-blind treatment period and a 4-7 day safety follow-up period. patients who are eligible for the double-blind treatment period will be randomized to one of following treatment groups: grt6005 high-dose range (400, 600 or 800 mcg), grt6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (cr) dose range (10, 20, 30, 40 or 50 mg) or placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of osteoarthritis (oa) of the knee * oa knee pain present for at least 3 months * oa knee pain is the predominant (ie, most painful) pain condition * patients require medication on at least 4 of 7 days per week to treat oa knee pain for at least 1 month. * dissatisfaction with current oa knee pain treatment and willingness to stop taking all pain medications except for the study drug and allowed rescue medication * average daily pain rating of at least 5 on a 0 to 10 point numerical rating scale during the 1 week prior to randomization * female patients either postmenopausal, surgically sterile or practicing a medically acceptable method of contraception * male patients either status post-bilateral vasectomy or using barrier contraception exclusion criteria: * knee pain due to a disorder other than oa * other pain that can confound the assessment of, or contribute to, pain at the reference knee * surgery at the reference knee within 6 months of screening or a history of joint replacement surgery at the reference knee * trauma to the reference knee within 6 months of screening with active symptoms * steroid injections in the reference knee within 3 months of screening * hyaluronic acid injections in the reference knee within 6 months of screening * body mass index \> 40 kg/m2 * patient with any protocol-excluded or clinically significant medical, surgical, or medication history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments

Keywords: osteoarthritis knee pain chronic oa arthritis
comparing the safety and effectiveness of different doses of morphine administered in spinal anethesia for pain relief after hip replacement surgery

Conditions: Analgesics, Opioid; Anesthesia, Spinal; Total Hip Replacement; Adverse Anesthesia Outcome

Summary: pain management after total hip replacement is one of the most important aspects of postoperative care for patients and clinicians alike. one of the most common techniques used in anesthesia for this procedure is spinal anesthesia with concurrent administration of opioids into spinal sac. addition of opioids not only prolongs the anesthesia but also provides pain relief after the procedure for a limited amount of time. because of its unique chemical properties morphine provides the longest pain relief amongst currently known opioids lasting up to 24 hours. unfortunately this beneficial effect is associated with both minor and serious adverse effects, most important of which is respiratory depression. to limit this potenitialy fatal adverse effect dosing of morphine must be very precise in order to balance advantages and risks. the aim of the study was to assess effectiveness and safety profile of different doses of morphine administered during spinal anesthesia for pain control.


Eligibility criteria:
inclusion criteria: * informed consent to participate in trial * qualification for total hip replacement surgery * asa physical status i-iii * bmi 19-30 * lack of contraindications for drugs and interventions used in trial exclusion criteria: * incapability to provide informed consent * contraindications for spinal anesthesia * preoperative chronic pain * chronic use of analgesics * obesity (bmi\>30) * allergies and other contraindications for drugs used in trial * mental or physical incapability to operate pca syringe pump
liposomal bupivacaine for post-operative pain control in adolescent bariatric patients

Conditions: Bariatric Surgery Candidate; Post-operative Pain

Summary: liposomal bupivacaine (trade name exparel) is a local analgesic that is designed to produce more long-term pain control. bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. typical length of therapeutic effect for standard bupivacaine is up to 6 hours. the liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.

use of liposomal bupivacaine has not been reported specifically for use in adolescent bariatric surgery. our rationale is based on the notion that for most minimally invasive procedures, methods currently used for pain control provide good outcomes that liposomal bupivacaine may not necessarily be able to improve upon. it is critically important to minimize the narcotics for our bariatric surgical patients so they are mobilized early and frequently to minimize their risk for a deep venous thrombosis, which could become a pulmonary embolus. in addition, as these patients are prone to constipation after their operation as a result of their 2 week protein sparing liquid diet preoperatively, avoiding narcotics can reduce their chances of further challenges in return of their bowel function. for these reasons, we seek to investigate whether incorporating liposomal bupivacaine in the analgesic regimen for patients undergoing a laparoscopic sleeve gastrectomy will lead to improvements in patient-reported outcomes and decreased opioid utilization.

Eligibility criteria:
inclusion criteria: * patients who are undergoing a laparoscopic sleeve gastrectomy for severe obesity who are between 13 and 2018 years of age. * only patients treated at the children's hospital of richmond at vcu will be included. exclusion criteria: * patients less than 13 or greater than 2018 years of age * patients with an allergy to bupivacaine * any patients undergoing any additional procedures at the time of the laparoscopic sleeve gastrectomy. * english or spanish proficiency will be necessary.

Keywords: liposomal bupivacaine exparel
lighting intervention to improve sleep

Conditions: Parkinson Disease; Sleep Disturbance

Summary: 50 participants with parkinson's disease will be recruited to complete actigraphy studies to assess sleep disturbances. for this, participants will wear an actigraph for seven days. thirty of these participants with sleep disturbance, will go on to receive a tailored lighting intervention (tli) to assess the effect on sleep, fatigue, and circadian entrainment via urinary melatonin levels.

participants will undergo one week of baseline data collection using the actigraph and light meter and one night of an overnight urine collection. at the completion of the baseline week, the lighting intervention will be installed in the participants home. participants will be exposed to the lighting intervention for 2 hours each morning after awakening for 4 weeks. during the last week of the lighting, participants will be asked to wear the actigraph and light meter again for 7 days and collect one overnight urine sample. participants will complete questionnaires before and after the intervention to further assess its effects.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease and * difficulties with sleep or cognition exclusion criteria: * there is no exclusion criteria
performance assessment of the fluorescence technique alone in the search for the sentinel node in breast surgery

Conditions: Breast Cancer

Summary: cohort, interventional, multicenter, non-randomized study to compare the performance of the icg fluorescence technique (icg) alone to the combined icg + isotopic technique in the detection of sentinel node. comparison of the performances of two techniques used in current practice, without modification of the patients' care plan. indeed, all patients receive both techniques, but the protocol allows to standardize the collection of the performances of each of the two techniques in order to compare them.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age on the day of inclusion, * presenting with breast cancer, * fulfilling the sentinel node search criteria of: * patient with carcinoma in situ with high risk of microinvasion: * nodular presentation, high grade with necrosis, * suspicion of microinvasion at biopsy, * radiological size of more than 40 mm, * need for mastectomy or extensive resection requiring a complex oncoplasty surgery (no size criteria, at the surgeon's discretion) * patient with t1-t2 invasive carcinoma and no lymph node involvement according to tumor-node-metastasis (tnm) classification (n0) on clinical and imaging (negative axillary echo or negative lymph node biopsy): * unifocal or bifocal proximal tumor * \< 5 cm (clinical), palpable or non-palpable (subcentimetric allowed) * in case of neoadjuvant chemotherapy: before or after if n0 and negative axillary echo or negative biopsy * benefiting from a french social security system * having been informed of the study and having freely given their informed consent to participate in the study. exclusion criteria: * pregnant or breastfeeding patient * patient not eligible for the sentinel node procedure (contraindication to surgery, n+ and/or m+ clinical or radiological, t3 and more, history of homolateral breast cancer surgery) * patient under guardianship or curators * patient under court protection * patient who does not understand french * patient already included in the study
efficacy and safety of natamycin and lactulose vaginal suppositories in treatment of vulvovaginal candidiasis

Conditions: Vulvovaginal Candidiasis, Genital

Summary: the purpose is to study superior efficacy of combination of natamycin and lactulose (natamycin 100 mg + lactulose 300 mg vaginal suppositories) compared to pimafucin (natamycin 100 mg vaginal suppositories), or lactulose 300 mg vaginal suppositories. the second objective of the study was to investigate the safety of the combination suppositories in the treatment of vulvovaginal candidiasis in non-pregnant adult females.


Eligibility criteria:
inclusion criteria: * two or more of the following signs and symptoms of vulvovaginal candidiasis: white or yellowish-white curd-like, thick or creamy vaginal discharge; vulvar itching, burning and pain; anogenital itching and burning; discomfort in the vulva; itching, burning, painful urination (dysuria); * yeast cells in the vaginal swab specimen; * vaginal ph ≤ 4.5. exclusion criteria: * a clinical and laboratory diagnosis of bacterial vaginosis; vulvovaginitis caused by specific pathogens such as trichomonas vaginalis, chlamydia trachomatis, neisseria gonorrhoeae; chronic inflammatory, atrophic, or oncologic diseases of the female genital tract; previous surgery on external or internal genitalia within 6 months; childbirth and abortion within 6 months.

Keywords: vulvovaginal candidiasis itching natamycin lactulose
trial of centanafadine efficacy and safety as monotherapy or as adjunct to ssri in adults with major depressive disorder

Conditions: Major Depressive Disorder

Summary: this is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (qd) extended-release (xr) capsules for the treatment of adult subjects diagnosed with major depressive disorder (mdd). the trial will evaluate the efficacy and safety of centanafadine qd xr capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (ssri), escitalopram.


Eligibility criteria:
key inclusion criteria: * male and female subjects between 18-65 years of age, with a primary diagnosis of major depressive disorder and in a current major depressive episode. * history of an inadequate response to at least 1 and no more than 3 antidepressant treatments in the current major depressive episode. key exclusion criteria: * subjects who report an inadequate response to more than 3 antidepressant treatments in the current episode. * subjects with a lifetime history of schizophrenia spectrum or other psychotic disorder, bipolar or related disorder, neurocognitive disorder, or personality disorder. * subjects with a current diagnosis of post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, or eating disorder (including anorexia nervosa or bulimia). * sexually active subjects, who could become pregnant, not agreeing to practice 2 sponsor approved methods of birth control or remain abstinent during the trial and for 30 days (females) or 90 days (males) after last dose of study drug.

Keywords: mdd centanafadine ssri depressive disorder depression depressive disorder, major mood disorders mental disorders behavioral symptoms
prevalence of colon cancer in pyogenic liver abscess

Conditions: Cryptogenic Pyogenic Liver Abscess

Summary: although a proportion of pyogenic liver abscess may originated from colonic mucosal lesions, the prevalence of colonic neoplasm in the patients with pyogenic liver abscess are still not evaluated yet. thus, our group will find the prevalence of colonic neoplasm in the group of cryptogenic pyogenic liver abscess by colonoscopic examination.


Eligibility criteria:
inclusion criteria: * pyogenic liver abscess radiologically and bacteriologically diagnosed exclusion criteria: * amebic liver abscess * other causes of pyogenic liver abscess such as cholangitis, liver cancer, complication of transarterial chemoembolization or radiofrequency ablation to hepatocellular carcinoma * refusal to colonoscopic examination * inadequate general patient status to perform the colonoscopic examination * patient who has had the screening colonoscopic examination within 1 year and showed normal finding or had 1 or 2 colon polyp in adequate exam

Keywords: pyogenic liver abscess colon cancer
effects of curcuminoids on coronary artery bypass grafting-related myocardial infarction study

Conditions: Coronary Artery Bypass Grafting

Summary: it is well-established that myocardial infarction (mi) associated with coronary artery bypass graft surgery (cabg) predicts the poor outcome. nevertheless, the cardioprotective therapies to limit myocardial injury after cabg are lacking. previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. the investigators aim to evaluate whether curcuminoids prevent mi after cabg, compared to placebo.


Eligibility criteria:
inclusion criteria: patients undergoing cabg without valve surgery exclusion criteria: * emergency cardiac surgery * any increase in ck-mb above upper limit of normal range (uln) at the time of randomization * patients with cholestatic jaundice (total bilirubin \> 2-fold uln) * severe liver disease (ast or alt \> 3-fold uln)

Keywords: myocardial infarction coronary artery bypass grafting anti-oxidant curcuminoids